OnKure, Inc. a precision oncology company, today announced that it has successfully closed a $54 million Series C financing. The financing was led by Surveyor Capital (a Citadel company) with participation from new investor Deep Track Capital, as well as existing investors Acorn Bioventures, Cormorant Asset Management, Perceptive Advisors, Samsara BioCapital, funds and accounts managed by BlackRock, and other undisclosed investors.
Who to call at OnKure Therapeutics, and when
A new round usually means OnKure Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
An alert the day OnKure Therapeutics raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at OnKure Therapeutics, from your own LinkedIn network
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
OnKure Therapeutics
Location
6707 WINCHESTER CIRCLE
Boulder, Colorado, United States
About
OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of best-in-class precision medicines that target biologically significant and well-validated pharmacological pathways, with a focus on oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Kα).
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment OnKure Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
BoulderBiotechnologyHealthcareTherapeuticsPharmaceuticalBiopharma